Cancer Treatment for Everyone

Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy

Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event that requires prompt identification and management. Although often referred to as pneumonitis, pulmonary toxicity associated with immunotherapy covers a broad and overlapping spectrum of pulmonary manifestations, and, once suspected, the range of differential diagnoses of infectious and neoplastic processes might make the diagnostic process challenging for physicians.

Numerous studies have shown that miRNA levels are closely related to the survival time of patients with colon, rectal, or colorectal cancer (CRC). However, the outcomes of different investigations have been inconsistent. Accordingly, a meta-analysis was conducted to study associations among the three types of cancers.

The short perioperative period, spanning several days pre- and postsurgery, is now believed to have a nonproportionally large impact on long-term cancer outcomes (1,2). Numerous physiological responses to the newly discovered cancer and to surgical resection trigger pro-metastatic processes that can affect minimal residual disease (MRD; single tumor cells/micrometastases).

Continued evolution in cancers gives rise to intra-tumour heterogeneity (ITH), which is a major mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin and drivers of ITH across cancer types are poorly understood. Here, we extensively characterise ITH across 2,778 cancer whole genome sequences from 36 cancer types.

Massive Bio, Inc., a leader in providing simplified and affordable access to precision oncology to cancer patients treated at community-based oncology practices, announced today that the first patient has been enrolled in a global registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool powered by a virtual tumor board (VTB) program. This registry will assess its clinical impact on world-wide patients with advanced cancer to facilitate clinical trial enrollment (CTE), as well as financial impact.

Carriers of germ-line mutations in BRCA1 and BRCA2 from families at high risk for cancer have been estimated to have an 85 percent risk of breast cancer. Since the combined frequency of BRCA1 and BRCA2 mutations exceeds 2 percent among Ashkenazi Jews, we were able to estimate the risk of cancer in a large group of Jewish men and women from the Washington, D.C., area.


This activity is designed to inform physicians about the current availability and use of targeted therapies and precision medicine in gastric (GC) and other gastrointestinal (GI) cancers.


Here, we have oral drugs. How do these oral oncolytics compare to the parenteral drugs–the only drugs, really, when I was growing up in medicine–in terms of use and in terms of access?


Two widely used regimens for advanced-stage follicular lymphoma led to similar high rates of long-term survival, as reported in the Journal of Clinical Oncology.


Continuing adjuvant aromatase inhibitor (AI) therapy for 2 years beyond the current standard 5 years of treatment yielded the same level of recurrence prevention as continuing the treatment for an extra 5 years, according to a report at the San Antonio Breast Cancer Symposium.


The FDA approved a next-generation sequencing test that can detect multiple mutations in any solid tumor.


Stay in Touch with Us

To speak with a dedicated cancer care specialist, contact us:


By submitting, you agree to our Terms And Conditions and have read and acknowledged our Privacy Statement.